EE200200185A - NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid - Google Patents

NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid

Info

Publication number
EE200200185A
EE200200185A EEP200200185A EEP200200185A EE200200185A EE 200200185 A EE200200185 A EE 200200185A EE P200200185 A EEP200200185 A EE P200200185A EE P200200185 A EEP200200185 A EE P200200185A EE 200200185 A EE200200185 A EE 200200185A
Authority
EE
Estonia
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba structural
Prior art date
Application number
EEP200200185A
Other languages
English (en)
Estonian (et)
Inventor
Hughes John
Singh Lakhbir
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200185A publication Critical patent/EE200200185A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200185A 1999-10-07 2000-10-05 NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid EE200200185A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (fr) 1999-10-07 2000-10-05 Complexes medicamenteux d'antagoniste de recepteur nk1 et d'analogue structurel gaba

Publications (1)

Publication Number Publication Date
EE200200185A true EE200200185A (et) 2003-04-15

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200185A EE200200185A (et) 1999-10-07 2000-10-05 NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid

Country Status (38)

Country Link
EP (2) EP1221950B1 (fr)
JP (2) JP2003510356A (fr)
KR (1) KR20020060192A (fr)
CN (1) CN1387434A (fr)
AP (1) AP2002002501A0 (fr)
AR (1) AR029646A1 (fr)
AT (1) ATE269072T1 (fr)
AU (2) AU7663300A (fr)
BG (1) BG106548A (fr)
BR (1) BR0014598A (fr)
CA (1) CA2385930A1 (fr)
CO (1) CO5280195A1 (fr)
CR (1) CR6614A (fr)
CZ (1) CZ20021116A3 (fr)
DE (1) DE60011650T2 (fr)
DK (1) DK1221950T3 (fr)
EA (1) EA004266B1 (fr)
EE (1) EE200200185A (fr)
ES (1) ES2220542T3 (fr)
GT (1) GT200000166A (fr)
HR (1) HRP20020286A2 (fr)
HU (1) HUP0203466A3 (fr)
IL (1) IL148965A0 (fr)
IS (1) IS6318A (fr)
MA (1) MA26826A1 (fr)
MX (1) MXPA02003484A (fr)
NO (1) NO20021625D0 (fr)
NZ (1) NZ517949A (fr)
OA (1) OA12063A (fr)
PA (1) PA8504301A1 (fr)
PE (1) PE20010708A1 (fr)
PL (1) PL357498A1 (fr)
PT (1) PT1221950E (fr)
SK (1) SK4542002A3 (fr)
TR (1) TR200200913T2 (fr)
UY (1) UY26376A1 (fr)
WO (2) WO2001024792A1 (fr)
ZA (1) ZA200202675B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084881A1 (fr) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE TROUBLES INTESTINAUX FONCTIONNELS UTILISANT DES MODULATEURS DE LA SOUS-UNITE $G(A)2$G(D) DES CANAUX CALCIQUES AVEC DES MODULATEURS DES MUSCLES LISSES
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (fr) 2010-07-30 2017-10-31 Toray Industries, Inc. Agent therapeutique ou prophylactique pour douleur neuropathique
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
WO2022234110A1 (fr) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Dérivés d'acide gamma-aminobutyrique destinée à être utilisée en cancérothérapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
IL148965A0 (en) 2002-11-10
HUP0203466A2 (hu) 2003-02-28
AR029646A1 (es) 2003-07-10
HRP20020286A2 (en) 2003-08-31
BR0014598A (pt) 2002-06-11
WO2001024792A1 (fr) 2001-04-12
DE60011650T2 (de) 2005-07-14
GT200000166A (es) 2002-03-30
MXPA02003484A (es) 2004-09-10
CA2385930A1 (fr) 2001-04-12
HUP0203466A3 (en) 2005-03-29
PE20010708A1 (es) 2001-07-27
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
OA12063A (en) 2006-05-03
CO5280195A1 (es) 2003-05-30
EP1233766A1 (fr) 2002-08-28
WO2001024792A9 (fr) 2002-09-06
SK4542002A3 (en) 2003-09-11
EP1221950B1 (fr) 2004-06-16
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
MA26826A1 (fr) 2004-12-20
JP2003510355A (ja) 2003-03-18
KR20020060192A (ko) 2002-07-16
WO2001024791A1 (fr) 2001-04-12
EP1221950A1 (fr) 2002-07-17
CZ20021116A3 (cs) 2003-05-14
NO20021625L (no) 2002-04-05
NO20021625D0 (no) 2002-04-05
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
ATE269072T1 (de) 2004-07-15
NZ517949A (en) 2003-08-29
CN1387434A (zh) 2002-12-25
CR6614A (es) 2003-12-04
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
TR200200913T2 (tr) 2002-09-23
DE60011650D1 (de) 2004-07-22
EA200200303A1 (ru) 2002-08-29
ZA200202675B (en) 2003-04-15
PT1221950E (pt) 2004-08-31
AU1696201A (en) 2001-05-10
ES2220542T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
EE200200185A (et) NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid
EE200300108A (et) Kondenseerunud heterotsüklilised suktsiinimiidiühendid ja nende analoogid kui tuuma hormooniretseptori funktsiooni modulaatorid
DK0833612T3 (da) Ny farmaceutisk sammensætning med bedøvende virkning
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
EE05585B1 (et) Indasoolihendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ning nende kasutamine
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
NO20022645D0 (no) Farmasöytisk superdisintegrerende stoff
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
DK0923550T3 (da) Acylaminoalkylen-amid-derivater som NK1- og NK2-antagonister
EE200100631A (et) Amlodipiini ja atorvastatiini ühised eelravimid
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
EE03668B1 (et) Stabiliseeritud farmatseutilised kompositsioonid kinupristiini ja dalfopristiini baasil ning nende valmistamine
ATE314846T1 (de) Synergistische wirkungen von amlodipin und dem hydroxylierten metabolit von atorvastatin
EE05262B1 (et) Leptiini v?i selle homoloogi v?i derivaadi kasutamine, farmatseutiline kompositsioon ja segu
DE50010255D1 (de) Dübel
HUP9903183A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions with analgetic activity
BR7701327U (pt) Escova dental com carga injetável
ITFI990215A0 (it) Uso della meftormina per la preparazione di composizioni farmaceutich e per l'inibizione dell'enzima dipeptidil peptidasi iv
ATE319448T1 (de) Therapeutische zusammensetzung von amlodipin und benazepril
ITMI991631A0 (it) Componente strutturale multifunzionale per quadri elettrici centralini e simili